LIFE.ME

Farmsintez PAO [LIFE.ME] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LIFE.ME Stock Summary

Top 10 Correlated ETFs

LIFE.ME

Top 10 Correlated Stocks

LIFE.ME

In the News

LIFE.ME Financial details

Company Rating
-
Market Cap
1.36B
Income
-56.83M
Revenue
247.67M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
119
Optionable
No
Shortable
Yes
Earnings
-
P/E
-6.54
Forward P/E
-
PEG
0.69
P/S
3.57
P/B
11.2
P/C
-
P/FCF
-198.75
Quick Ratio
0.01
Current Ratio
0.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.13
EPS next Y
-
EPS next Q
-
EPS this Y
-70.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
6.15%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-2.7%
SMA50
-11.72%
SMA100
-26.03%
Inst Own
-
Inst Trans
-
ROA
-16%
ROE
-89%
ROC
-0.84%
Gross Margin
21%
Oper. Margin
-36%
Profit Margin
-55%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.905-4.9
52W High
-20.5%
52W Low
+6%
RSI
33.96
Rel Volume
-
Avg Volume
-
Volume
430K
Perf Week
-3.34%
Perf Month
-6.74%
Perf Quarter
-27.06%
Perf Half Y
-23.92%
-
-
-
-
Beta
-0.026
-
-
Volatility
0.03%, 0.05%
Prev Close
-0.31%
Price
3.18
Change
-0.93%

Something similar

Top by Market Cap
TL0.DE
MIX.JO
VTI
ABEC.DE
ABEA.DE
Top Correlated ETFs
EJP3.MI
KJ7.SI
Top Correlated Stocks
VLHZ.ME
2440.TW
9103.TW
1760.TW
1486.HK
Similar Market Cap
DISIX
JACK
4240.SR
UTZ
4562.TW

Company Profile

Healthcare Biotechnology
  • Market Capitalization 1.36B
  • Employee 119
  • CEO Mr. Petr Vladimirovich Kurglyakov
  • Headquarters Saint Petersburg,RU
  • IPO Date 2010-11-25
  • Website https://www.pharmsynthez.com

Public Joint-Stock Company ‘Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company ‘Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.